+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

GeoVax Labs Inc (GOVX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • August 2024
  • GlobalData
  • Geovax
  • ID: 1292024
GeoVax Labs Inc (GOVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GeoVax Labs Inc (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic, and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc Key Recent Developments

  • Aug 08, 2024: GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
  • Aug 06, 2024: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
  • Jul 09, 2024: GeoVax Provides First Half 2024 Business Update
  • May 29, 2024: GeoVax to Present at BIO International Convention 2024

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • GeoVax Labs Inc - Key Facts
  • GeoVax Labs Inc - Key Employees
  • GeoVax Labs Inc - Key Employee Biographies
  • GeoVax Labs Inc - Major Products and Services
  • GeoVax Labs Inc - History
  • GeoVax Labs Inc - Company Statement
  • GeoVax Labs Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • GeoVax Labs Inc - Business Description
  • R&D Overview
  • GeoVax Labs Inc - Corporate Strategy
  • GeoVax Labs Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • GeoVax Labs Inc - Strengths
  • GeoVax Labs Inc - Weaknesses
  • GeoVax Labs Inc - Opportunities
  • GeoVax Labs Inc - Threats
  • GeoVax Labs Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • GeoVax Labs Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Aug 08, 2024: GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
  • Aug 06, 2024: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
  • Jul 09, 2024: GeoVax Provides First Half 2024 Business Update
  • May 29, 2024: GeoVax to Present at BIO International Convention 2024
  • May 14, 2024: Geovax Reports First Quarter 2024 Financial Results And Provides Business Update
  • May 07, 2024: GeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
  • Mar 06, 2024: GeoVax Achieves Milestone In Transition To Commercially Validated Manufacturing System
  • Feb 29, 2024: GeoVax Reports 2023 Year-End Financial Results And Provides Business Update
  • Jan 08, 2024: GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
  • Jan 03, 2024: GeoVax Announces Issuance of Malaria Vaccine Patent
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • GeoVax Labs Inc, Key Facts
  • GeoVax Labs Inc, Key Employees
  • GeoVax Labs Inc, Key Employee Biographies
  • GeoVax Labs Inc, Major Products and Services
  • GeoVax Labs Inc, History
  • GeoVax Labs Inc, Subsidiaries
  • GeoVax Labs Inc, Key Competitors
  • GeoVax Labs Inc, Ratios based on current share price
  • GeoVax Labs Inc, Annual Ratios
  • GeoVax Labs Inc, Interim Ratios
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • GeoVax Labs Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • GeoVax Labs Inc, Performance Chart (2019 - 2023)
  • GeoVax Labs Inc, Ratio Charts
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sanofi
  • Protein Sciences Corp
  • Profectus BioSciences Inc
  • Pfizer Inc
  • Novavax Inc
  • Moderna Inc
  • Merck & Co Inc
  • Juno Therapeutics Inc
  • Johnson & Johnson
  • Janssen Pharmaceuticals Inc
  • Inovio Pharmaceuticals Inc
  • GlaxoSmithKline AG
  • Dynavax Technologies Corp
  • Curevac NV
  • BioNTech SE
  • Ayala Pharmaceuticals Inc.
  • AstraZeneca Plc